Cuatrecasas advises JME on Longevity I fund
Cuatrecasas has advised JME Venture Capital on the creation of JME Longevity I, a new venture capital fund that will invest in companies whose products and services help improve quality of life and life expectancy.
The fund’s scope covers businesses linked to life sciences, healthcare biotechnology, medical technology, digital health, healthcare services, pharmaceuticals, medical devices, wellness, prevention, diagnosis, treatment and assisted care.
JME Longevity I will concentrate on three areas: diagnosis and prevention, therapies, and platforms that develop better therapies. By geography, investments could be split roughly between the European Union (70%), the United States (20%) and Asia (10%). JME Venture Capital has already launched up to four venture capital funds. It is now moving into longevity, a field distinct from its earlier tech activity that requires a dedicated strategy and fund, says Cuatrecasas.
Advisory team
The Cuatrecasas team that advised on the transaction comprised partners Jorge Canta, Paz Irazusta, as well as Juan Manuel Navajas from the firm’s Funds group.